Summary The pharmaceutical industry is important because it is a major source of medical innovation. In our Report we have analyzed the Indian Pharmaceutical Industry and we have also done Market analysis of Panacea Biotec. India’s pharmaceutical market grew at 15. 7 per cent during December 2011. Globally, India ranks third in terms of manufacturing pharma products by volume. The Pharmaceutical Market is ranked 14th in the world. By 2015 it is expected to reach top 10 in the world beating Brazil, Mexico, South Korea and Turkey.
More importantly, the incremental market growth of US$ 14billion over the next decade is likely to be the third largest among all markets. The US and China are expected to add US$ 200bn and US$ 23bn respectively. Generics: India tops the world in exporting generic medicines worth US$ 11 billion. The Indian generic drug market is to grow at a CAGR of around 17 per cent between 2010-11 and 2012-13. Over the next few years, it is expected that the patent laws will provide impetus to the launch of patent-protected products.
Such products have the potential to capture up to a 10% share of the market by 2015, implying the market size of US $2bn. R&D: According to Battelle R&D magazine, gross expenditure on R&D (GERD) by India for 2012 was projected to be US$ 41 billion in purchasing power parity terms, which works out to 0. 8 per cent of GDP. This is low both in absolute terms and as a proportion of GDP compared to other countries. This is partly because the size of the R&D base and absorption capacity is not commensurate with requirements.
... . 3. 2 CURRENT COMPETITIVE POSITION Name Market Share Selling Product Price Product Range Characteristics Company 1 22% Basic & Value $87 $115 5-50 ... & Mortar distribution points.The company has invested in some call center and online trade in the business market. For the basic product ...
Demand: The demand for pharmaceutical products in India is significant and is driven by many factors like low drug penetration, rising middle-class & disposable income, increased government & private spending on healthcare infrastructure, increasing medical insurance penetration, changing demographic pattern and rise in chronic lifestyle-related diseases; adoption of product patents, and aggressive market penetration driven by the relatively smaller companies.
According to CARE research demand triggers for the growth are: * Between 2010 and 2015 patent drugs worth US$171 bn are estimated to go off-patent leading to a huge surge in generic products. * High margin pharma export business is expected to grow at a higher rate than domestic market given increased in outsourcing activities. * Increased M&A activities is set to consolidate the market which widens geographic reach, strengthens distribution network and venture into new therapeutic segments.
Indian companies files the highest number of ANDA’s with USFDA leading to greater chances of approvals and thereby increasing export to regulated markets especially the US. * There are currently approximately 175 USFDA and nearly 90 UK-MHRA approved pharma manufacturing plants in India which can supply high quality pharma products globally. * Growth from rural markets will outstrip overall pharma market growth, albeit at lower margins, given lower penetration of 18-19% coupled with rising income level and awareness.
Biopharmaceuticals is another potential high growth segment for Indian pharma growing at double digit driven by the vaccines market. Pharmaceutical Company – Panacea Biotec Panacea Biotec is an Indian research based pharmaceutical and health management company involved in research, manufacturing, and marketing of pharmaceutical formulations, vaccines, and natural products. Panacea Biotec has engineered its sales and marketing network for pharmaceutical formulations into strategic business units (SBUs), which comprise Critical Care, Diacar, Procare and Growcare.
... Pharmaceutical companies promote their products in a variety of ways. There are several different markets these companies are ... companies could market their products in an ethical and safe way. REFERENCES Defilippis, C. J. "Merger - A Different Perspective," Pharmaceutical ... , Jill. "The DTC Dilemma: As pharmaceutical companies promote Products directly to consumers, patients are demanding mediations ...
The company has also moved ahead to launch other new SBU, viz. Onctrust & Value India. The aim of each SBU is to attain leadership position in its respective markets and establish brand equity in respective therapeutic segment by implementing the concept of Customer Relation Management (CRM) for better coverage and servicing of customers. The SBUs promote a portfolio of brands with a special focus on Orthopedicians, Cardiologists, Diabetologists, Physicians, Nephrologists, Pulmonologists, Surgeons, Dentists, ENT (Ear, Nose and Throat) specialists, Pediatricians and Gastro – Enterologists.
Panacea Biotec is uniquely able to take its roots to international marketing. The Company has started international marketing for its branded formulations in CIS countries, South East Asia, Eastern Europe and African Region. Today the Company’s products are available to people in over 35 countries across the globe. The Company achieved a remarkable export turnover by way of supplies of Oral Polio Vaccines to various countries including Abidjan, Afghanistan, Angola, Bangladesh, Cameroon, Chad, Congo, Ethiopia, Indonesia, Kenya, Myanmar, Nepal, Nigeria, Somalia, Sudan, Turkey and Uganda through UNICEF against its global tenders.
The company continues to make significant contributions towards preventive therapies against deadly diseases. During the year ended March 31, 2012, the Company registered a net turnover of Rs. 6,883. 8 million as against Rs. 11,304. 6 million during the corresponding financial year. Research Methodology Objectives: 1) Analysis of Indian Pharmaceutical Industry 2) Market Analysis of Panacea Biotec Review of Literature Pharmaceutical Sector Indian Pharma Industry – an overview
The demand for pharmaceutical products in India is significant and is driven by low drug penetration, rising middle-class & disposable income, increased government & private spending on healthcare infrastructure, increasing medical insurance penetration etc. The Indian pharmaceutical industry is growing at about 8 to 9 percent annually according to “A Brief Report Pharmaceutical Industry in India,” published in January 2011. The Pharmaceutical industry in India meets around 70% of the country’s demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables.
... are poor – in the same India where millions use smartphones. Within India, there are many different countries. There is no doubt that in ... go. The question of whether or not India is a developed or developing country is not so simple. To understand the ... Even after 66 years of independence, India is still labeled as a developing country. I think as a nation, we have miles to ...
There are approximately 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).
I. Current Scenario: India’s pharmaceutical market grew at 15. 7 per cent during December 2011. Globally, India ranks third in terms of manufacturing pharma products by volume. The Pharmaceutical Market is ranked 14th in the world. By 2015 it is expected to reach top 10 in the world beating Brazil, Mexico, South Korea and Turkey.